Trial Profile
Phase II Study of Nimotuzumab and Concurrent Radiotherapy and Capecitabine for Inoperable Locally Advanced or Recurrent Gastric Cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Nimotuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 28 May 2013 Planned End Date changed from 1 May 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 18 Aug 2010 New trial record